NASDAQ:WVE - Wave Life Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$43.65 -6.80 (-13.48 %)
(As of 06/19/2018 01:37 PM ET)
Previous Close$50.30
Today's Range$39.80 - $50.33
52-Week Range$15.15 - $55.95
Volume44,719 shs
Average Volume162,226 shs
Market Capitalization$1.47 billion
P/E Ratio-13.10
Dividend YieldN/A
Beta0.64
Wave Life Sciences logoWave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Receive WVE News and Ratings via Email

Sign-up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:WVE
CUSIPN/A
Phone65-6236-3388

Debt

Debt-to-Equity Ratio0.04
Current Ratio7.24
Quick Ratio7.24

Price-To-Earnings

Trailing P/E Ratio-13.10
Forward P/E Ratio-9.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.70 million
Price / Sales343.30
Cash FlowN/A
Price / CashN/A
Book Value$5.03 per share
Price / Book8.68

Profitability

EPS (Most Recent Fiscal Year)($3.85)
Net Income$-102,030,000.00
Net Margins-2,613.03%
Return on Equity-76.93%
Return on Assets-61.14%

Miscellaneous

Employees168
Outstanding Shares29,100,000

Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd (NASDAQ:WVE) issued its earnings results on Wednesday, May, 9th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.90) by $0.36. The company had revenue of $1.42 million for the quarter, compared to analysts' expectations of $6.59 million. Wave Life Sciences had a negative return on equity of 76.93% and a negative net margin of 2,613.03%. View Wave Life Sciences' Earnings History.

When is Wave Life Sciences' next earnings date?

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Wave Life Sciences.

What price target have analysts set for WVE?

4 brokerages have issued 12-month target prices for Wave Life Sciences' stock. Their predictions range from $40.00 to $65.00. On average, they expect Wave Life Sciences' stock price to reach $56.75 in the next year. View Analyst Ratings for Wave Life Sciences.

Who are some of Wave Life Sciences' key competitors?

Who are Wave Life Sciences' key executives?

Wave Life Sciences' management team includes the folowing people:
  • Dr. Paul B. Bolno, Pres, CEO & Director (Age 44)
  • Mr. Keith Regnante, Chief Financial Officer (Age 48)
  • Dr. Michael A. Panzara, Franchise Lead of Neurology (Age 51)
  • Dr. Takeshi Wada, Scientific Advisor (Age 56)
  • Mr. Kyle B. Moran, Sr. VP of Supply Chain & Operations (Age 47)

Has Wave Life Sciences been receiving favorable news coverage?

Media stories about WVE stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Wave Life Sciences earned a media sentiment score of 0.06 on Accern's scale. They also assigned headlines about the company an impact score of 46.64 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP (8.90%), KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP (8.90%), Redmile Group LLC (7.69%), BB Biotech AG (3.08%), BlackRock Inc. (3.01%) and Eventide Asset Management LLC (1.30%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Keith Regnante, Masaharu Tanaka, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

Which institutional investors are selling Wave Life Sciences stock?

WVE stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, BlackRock Inc., Point72 Asset Management L.P., Eventide Asset Management LLC, Bailard Inc., Schwab Charles Investment Management Inc., JPMorgan Chase & Co. and A.R.T. Advisors LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Chris Francis, Keith Regnante, Masaharu Tanaka, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.

Which institutional investors are buying Wave Life Sciences stock?

WVE stock was bought by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Artal Group S.A., DAFNA Capital Management LLC, BB Biotech AG, Platinum Investment Management Ltd., Redmile Group LLC, Citadel Advisors LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Wave Life Sciences.

How do I buy shares of Wave Life Sciences?

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $43.55.

How big of a company is Wave Life Sciences?

Wave Life Sciences has a market capitalization of $1.47 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]


MarketBeat Community Rating for Wave Life Sciences (WVE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.